| Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene |
NCT01380600: Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma |
|
|
| Completed | 1b | 15 | RoW | Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594), JX-594 | Jennerex Biotherapeutics, Samsung Medical Center | Carcinoma, Colorectal | 11/12 | 12/15 | | |
NCT00629759: A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma |
|
|
| Completed | 1 | 14 | RoW | JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF) | Jennerex Biotherapeutics, Green Cross Corporation | Neoplasms, Liver | 07/07 | 08/07 | | |
NCT00625456: Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors |
|
|
| Completed | 1 | 23 | US, Canada | Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594), JX-594 | Jennerex Biotherapeutics | Melanoma, Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck | 04/10 | 06/14 | | |
NCT01169584: Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients |
|
|
| Completed | 1 | 6 | US | Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594), Pexa-Vec | Jennerex Biotherapeutics, Solving Kids' Cancer | Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Wilm's Tumor, Ewing's Sarcoma | 03/12 | 11/14 | | |
